Literature DB >> 1907770

Disturbance of basal and stimulated serum levels of intact parathyroid hormone in primary hyperparathyroidism.

S Ljunghall1, K Larsson, E Lindh, U Lindqvist, J Rastad, G Akerström, L Wide.   

Abstract

In patients with primary hyperparathyroidism, measurements were made of basal and stimulated levels of intact parathyroid hormone (PTH). The basal PTH values were elevated in all but six of 89 patients and provided clear separation towards normal individuals (n = 75) and patients with hypercalcemia of other origin (n = 34). The PTH value correlated with the serum calcium concentration in hyperparathyroidism and with the weight of excised parathyroid adenomas but not with that of chief cell hyperplasias. A constant ethylenediaminetetraacetic acid infusion during 60 minutes of induced essentially linear reductions of plasma-ionized calcium concentrations, averaging 0.02 mmol/L/10 minutes, which were associated with swift, curvilinear, elevations of PTH levels that reached a plateau after 10 to 20 minutes. The increment in serum PTH level correlated with the basal PTH value both in patients with hyperparathyroidism and controls. However, in proportion to the much greater glandular mass in the patients with hyperparathyroidism, the secretion of PTH was relatively reduced. The findings support the value of the intact PTH assay in the differential diagnosis of hypercalcemia and show that PTH secretion in vivo is extremely sensitive to hypocalcemic stimulation, that the pathological parathyroid tissue in hyperparathyroidism is characterized by a reduction of hormone release per unit weight, and that the hormone secretion in hyperparathyroidism operates closer to its maximal capacity than under normal circumstances.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907770

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Cellular physiology and pathophysiology of the parathyroid glands.

Authors:  G Akerström; J Rastad; S Ljunghall; P Ridefelt; C Juhlin; E Gylfe
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

2.  Intact serum parathyroid hormone levels increase during running exercise in well-trained men.

Authors:  H Salvesen; A G Johansson; P Foxdal; L Wide; K Piehl-Aulin; S Ljunghall
Journal:  Calcif Tissue Int       Date:  1994-04       Impact factor: 4.333

3.  Response of parathyroid hormone to exercise and bone mineral density in adolescent female athletes.

Authors:  H Takada; K Washino; T Hanai; H Iwata
Journal:  Environ Health Prev Med       Date:  1998-01       Impact factor: 3.674

4.  Suppressibility of serum levels of PTH by calcium in the immediate postoperative period after surgery for primary hyperparathyroidism.

Authors:  A Bergenfelz; B Ahrén
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

5.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

6.  Immunoheterogeneity of parathyroid hormone pre- and postoperatively in primary hyperparathyroidism.

Authors:  A Bergenfelz; S Valdermarsson; B Ahrén
Journal:  Langenbecks Arch Chir       Date:  1995

7.  Dynamics of parathyroid hormone release and serum calcium regulation after surgery for primary hyperparathyroidism.

Authors:  W Graf; J Rastad; G Akerström; L Wide; S Ljunghall
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

8.  Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range.

Authors:  Fabio Medas; Enrico Erdas; Giulia Loi; Francesco Podda; Lucia Barca; Giuseppe Pisano; Pietro Giorgio Calò
Journal:  BMC Surg       Date:  2019-04-24       Impact factor: 2.102

9.  Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study.

Authors:  Julie M Paik; Gary C Curhan; Eric N Taylor
Journal:  BMJ       Date:  2012-10-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.